RxDoctor Payments Data

Michael Pendleton, MD

Family Medicine · Louisville, KYNPI 1922211556

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $29,250 of the $29,413 with a category attached, or 99.4%. Organon accounts for 66.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $15,540 and has fallen 82.1% since, to $2,784 in 2024. Among family medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,413in general payments, 2019–2025

Across 33 payments — averaging $891.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organon$20K
  • Merck$10K
  • GSK$33
  • Hologic Sales And Service, LLC$16
  • Agile Therapeutics, Inc.$15
  • Amarin Pharma, Inc.$14
  • plus $13 from 1 others

What the payments were for

  • Speaking & faculty fees$29,25099%
  • Food & beverage$1631%

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,413 in reported general payments places this provider in the 95th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$74,621
Medicare patients
237
Services billed
780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide49$51,477
EliquisApixaban35$49,795
XareltoRivaroxaban19$32,362
JanuviaSitagliptin Phosphate29$26,620
JardianceEmpagliflozin18$26,242
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$21,169
OzempicSemaglutide16$17,555
TrulicityDulaglutide16$16,377
Novolog FlexpenInsulin Aspart15$3,697
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,026
Estradiol Valerate24$2,860
Gabapentin137$2,621
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen118$2,619
Estradiol23$2,540
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen138$2,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$9,672$26,62029 claims
GSKTrelegy Ellipta$33$21,16915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →